VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Novartis Pharmaceuticals Canada Inc. announced today that Lucentis (ranibizumab), the treatment for several major causes of vision loss, has been approved by Health Canada for the treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).

8 Oct 2014

NF-kB molecule may help malignant cells hide from the immune system

A molecule that helps cancer cells evade programmed self-destruction, an internal source of death, might also help malignant cells hide from the immune system, an external source of death.

8 Oct 2014

CTRC researcher receives special $1.62 million orphan disease grant from FDA

A researcher at the Cancer Therapy & Research Center is the leader on a study receiving a special $1.62 million orphan disease grant from the Food & Drug Administration.

5 Oct 2014

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.

29 Sep 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).

22 Sep 2014

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial.

17 Sep 2014

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

16 Sep 2014

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma (ESCC), according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

16 Sep 2014

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.

15 Sep 2014

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Oraya Therapeutics Inc. announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone.

15 Sep 2014

Professor receives award for development of anti-angiogenic therapy for retinal disease

Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal.

11 Sep 2014

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world.

4 Sep 2014

New way to reduce abnormal blood vessel growth and leakage in eye

Working with mice, a multicenter team of researchers has found a new way to reduce the abnormal blood vessel growth and leakage in the eye that accompany some eye diseases. The finding could lead to the development of new drugs for wet macular degeneration and diabetic macular edema.

4 Sep 2014

VEGF News and Research

Further Reading

Health Canada approves Lucentis (ranibizumab) for myopic CNV

NF-kB molecule may help malignant cells hide from the immune system

CTRC researcher receives special $1.62 million orphan disease grant from FDA

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

NCCN ORP awards four research grants to advance development of nintedanib

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Ramucirumab effective second-line option for NSCLC

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Professor receives award for development of anti-angiogenic therapy for retinal disease

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

New way to reduce abnormal blood vessel growth and leakage in eye

Using molecular imaging probes diabetic retinopathy can be detected at molecular level

Reticular pseudodrusen predicts late-stage AMD

Choroidal consequences differ between anti-VEGF therapies

Sheffield Teaching Hospitals begins treating wet AMD patients with Oraya Therapy

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

First-line sunitinib superior to everolimus for metastatic RCC

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo